AbbVie presented new clinical data at the European Hematology Association (EHA) 2026 Congress showcasing progress in treatments for various blood cancers, including multiple myeloma, follicular lymphoma, and leukemia. Key highlights include promising results from epcoritamab in follicular lymphoma and large B-cell lymphoma, as well as updates on venetoclax and investigational drugs like etentamig and pivekimab sunirine. These findings reinforce AbbVie's commitment to advancing blood cancer therapies and improving patient outcomes. The company plans to continue research and development to expand treatment options and address unmet medical needs in hematologic cancers.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
